X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Abecma (idecabtagene vicleucel) is a CAR T cell therapy that recognizes and binds to BCMA on the surface of multiple myeloma cells. It is approved for the treatment of triple-class exposed relapsed or refractory multiple myeloma.
Lead Product(s): Idecabtagene Vicleucel
Therapeutic Area: Oncology Product Name: Abecma
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Recipient: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2024
Details:
The proceeds will fund commercial launches of FDA-approved gene therapies, Lyfgenia (lovotibeglogene autotemcel) for sickle cell disease, Zynteglo (betibeglogene autotemcel) for beta-thalassemia and Skysona (elivaldogene autotemcel) for cerebral adrenoleukodystrophy.
Lead Product(s): Lovotibeglogene Autotemcel
Therapeutic Area: Hematology Product Name: Lyfgenia
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Hercules Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing March 18, 2024
Details:
Through the agreement, Bluebird Bio will commercialize Lyfgenia (lovotibeglogene autotemcelsickle). It is approved for the treatment of patients 12 years of age or older with sickle cell disease and a history of vaso-occlusive events.
Lead Product(s): Lovotibeglogene Autotemcel
Therapeutic Area: Hematology Product Name: Lyfgenia
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Medicaid
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 11, 2024
Details:
Under the acquisition, Regeneron will have full development and commercialization rights to its pipeline of investigational novel immune cell therapies, including Abecma (idecabtagene vicleucel) along with its discovery and clinical manufacturing capabilities.
Lead Product(s): Idecabtagene Vicleucel
Therapeutic Area: Oncology Product Name: Abecma
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: $5.0 million
Deal Type: Acquisition January 30, 2024
Details:
bluebird will support commercialization and manufacturing for its three approved gene therapies, Zynteglo (betibeglogene autotemcel) for beta-thalassemia, Skysona (elivaldogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel) for sickle cell disease.
Lead Product(s): Betibeglogene Autotemcel
Therapeutic Area: Genetic Disease Product Name: Zynteglo
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering December 18, 2023
Details:
Abecma (idecabtagene vicleucel) is a BCMA directed CAR-T cell immunotherapy, for patients with relapsed or refractory multiple myeloma (RRMM) who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.
Lead Product(s): Idecabtagene Vicleucel
Therapeutic Area: Oncology Product Name: Abecma
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Recipient: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
FDA approved, Casgevy(exagamglogene autotemcel) and Lyfgenia(lovotibeglogene autotemcel), representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older.
Lead Product(s): Lovotibeglogene Autotemcel
Therapeutic Area: Hematology Product Name: Lyfgenia
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Recipient: Vertex Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2023
Details:
Abecma (idecabtagene vicleucel) is a CAR T cell therapy that recognizes and binds to BCMA on the surface of multiple myeloma cells, for earlier lines of triple-class exposed relapsed or refractory multiple myeloma (RRMM).
Lead Product(s): Idecabtagene Vicleucel
Therapeutic Area: Oncology Product Name: Abecma
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Recipient: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
Under the terms of the agreement, rights to the PRV will transfer to the buyer which is contingent upon the U.S. Food and Drug Administration’s approval of the BLA for lovotibeglogene autotemcel (lovo-cel) and granting of the PRV.
Lead Product(s): Lovotibeglogene Autotemcel
Therapeutic Area: Hematology Product Name: Lovo-cel
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $103.0 million Upfront Cash: Undisclosed
Deal Type: Financing October 30, 2023
Details:
Lovo-cel (lovotibeglogene autotemcel) is a one-time gene therapy being investigated for sickle cell disease (SCD), that is designed to add functional copies of a modified form of the β-globin gene (βA-T87Q-globin gene) into a patient’s own hematopoietic stem cells.
Lead Product(s): Lovotibeglogene Autotemcel
Therapeutic Area: Hematology Product Name: Lovo-cel
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
